Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) Director Arthur Henry Willms purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 25th. The stock was bought at an average cost of C$2.76 per share, for a total transaction of C$27,600.00.

Cardiome Pharma Corp (TSE COM) opened at 2.83 on Monday. The company’s market cap is $95.66 million. Cardiome Pharma Corp has a 12-month low of $2.63 and a 12-month high of $6.06. The company’s 50 day moving average is $5.11 and its 200 day moving average is $4.72.

WARNING: “Insider Buying: Cardiome Pharma Corp (COM) Director Acquires C$27,600.00 in Stock” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/insider-buying-cardiome-pharma-corp-com-director-acquires-c27600-00-in-stock/1527855.html.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Cardiome Pharma Corp in a report on Wednesday, May 17th.

About Cardiome Pharma Corp

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients.

Receive News & Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.